Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
Abstract Background Nivolumab is an anti-PD1 checkpoint inhibitor active in patients with advanced melanoma and as adjuvant therapy in high-risk metastatic melanoma patients. Methods In this single-center retrospective analysis, we investigated the CD73 enzyme activity in patients with metastatic me...
保存先:
| 主要な著者: | , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMC
2017-12-01
|
| シリーズ: | Journal of Translational Medicine |
| 主題: | |
| オンライン･アクセス: | http://link.springer.com/article/10.1186/s12967-017-1348-8 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|